Results In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database
With respect to the primary endpoint of A1C reduction from baseline, dulaglutide 4.5 mg was superior to the 1.5 mg dose at Week 36 under the treatment regimen estimand (mean change from baseline [mean baseline 8.6%]: dulaglutide 1.5 mg -1.54%, dulaglutide 4.5 mg -1.77%
What the research actually says about GLP-1 and hair loss The conversation around GLP-1 medications and hair loss has shifted dramatically over the past few years
Conclusion: Peptides for Long COVID Recovery Deserve Serious Clinical Attention Long COVID is real, biologically complex, and poorly served by the current standard of care for a significant proportion of patients
For use by qualified researchers in suitably equipped laboratory environments only